Top Page
Cyclopharm Limited
(Sydney:CYC)
Cyclopharm Limited (CYC) vs. iShares MSCI Australia ETF (EWA)
Cyclopharm Limited Business Overview & Revenue Model
Cyclopharm Limited Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 27.57M | 27.14M | 23.22M | 17.70M | 14.68M | Gross Profit |
| 17.93M | 4.50M | 5.94M | 3.20M | 2.08M | EBIT |
| -14.35M | -9.22M | -7.28M | -6.43M | -8.08M | EBITDA |
| -13.69M | -3.03M | -5.36M | -4.19M | -4.86M | Net Income Common Stockholders |
| -13.20M | -4.70M | -6.61M | -5.04M | -6.04M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 20.57M | 11.73M | 20.30M | 29.25M | 1.87M | Total Assets |
| 62.13M | 45.91M | 49.54M | 55.74M | 28.28M | Total Debt |
| 8.29M | 4.23M | 4.33M | 4.51M | 4.71M | Net Debt |
| -12.28M | -7.50M | -15.96M | -24.74M | 2.83M | Total Liabilities |
| 19.40M | 13.65M | 13.01M | 12.67M | 11.16M | Stockholders Equity |
| 42.73M | 32.26M | 36.54M | 43.07M | 17.12M |
| Cash Flow | Free Cash Flow | |||
| -13.55M | -7.74M | -8.21M | -2.79M | -9.47M | Operating Cash Flow |
| -12.57M | -7.20M | -6.66M | -1.63M | -8.93M | Investing Cash Flow |
| -971.86K | -508.47K | -1.55M | -1.16M | -874.19K | Financing Cash Flow |
| 22.22M | -1.02M | -725.64K | 30.17M | -985.96K |
Cyclopharm Limited Technical Analysis
Cyclopharm Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $17.63B | 47.64 | 20.61% | 1.61% | 6.35% | 5.97% | |
69 Neutral | $118.21B | 28.37 | 15.38% | 1.73% | 8.00% | 9.09% | |
69 Neutral | $1.31B | 78.75 | 9.23% | ― | 10.79% | 5.20% | |
61 Neutral | AU$19.76M | 140.00 | -3.11% | ― | 89.13% | 69.57% | |
54 Neutral | $5.37B | 3.35 | -45.10% | 2.79% | 16.77% | -0.01% | |
53 Neutral | AU$702.83M | ― | -112.97% | ― | ― | -84.82% | |
44 Neutral | AU$118.92M | ― | -35.20% | ― | 4.68% | -155.42% |
Cyclopharm Limited Corporate Events
Cyclopharm Limited has secured a five-year patent extension for its Technegas® Kit in the United States, extending exclusivity until 2031. This extension provides a significant competitive advantage in the U.S. market, allowing Cyclopharm to capitalize on the commercial and clinical potential of Technegas® without the threat of generic competition. The extension underscores the strong clinical profile of Technegas® and supports Cyclopharm’s strategic efforts to expand its market presence and innovation in pulmonary imaging technologies.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited announced that all resolutions proposed at its Annual General Meeting on May 30, 2025, were successfully passed. This includes approvals related to remuneration reports, director re-elections, and performance rights grants, which reflect strong shareholder support and may positively impact the company’s governance and operational strategies.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited has released a presentation containing forward-looking statements and projections about its future financial performance and market conditions. The company emphasizes that these projections are based on assumptions and are subject to uncertainties, and it does not guarantee their accuracy. The release highlights the company’s cautious approach to future predictions and its focus on managing stakeholder expectations.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited reported a record year in 2024, marked by the commencement of commercial sales in the United States following FDA approval. The company’s revenue reached $27.6 million, with Technegas sales contributing significantly. Despite a loss after tax of $13.2 million, Cyclopharm’s strategic expansion into the US market and its growing third-party distribution business are set to drive future growth. The company’s focus on expanding the use of Technegas for conditions beyond pulmonary embolism, such as COPD and asthma, indicates potential for accessing larger markets and achieving long-term growth.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited has entered a new growth phase following the USFDA approval of Technegas™ for lung imaging, which has significantly boosted its sales in the United States. The company achieved a 131% increase in US sales in 2024, with continued momentum into 2025, and has secured key agreements with major healthcare providers, enhancing its market reach. The expansion into the US market is expected to accelerate research into new clinical applications, potentially unlocking a global market opportunity estimated at US$900 million. Additionally, Cyclopharm is strengthening its third-party distribution business, contributing to its revenue diversity and margin resilience.
The most recent analyst rating on (AU:CYC) stock is a Buy with a A$2.70 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
Cyclopharm Limited has announced its Annual General Meeting, scheduled for May 30, 2025, in Kingsgrove, NSW. The meeting will address several key resolutions, including financial statements, director re-election, and approval of performance rights and remuneration. This meeting is crucial for stakeholders as it will determine strategic decisions impacting the company’s governance and financial strategies.
Cyclopharm Limited announced the installation of its Technegas® technology at Brooke Army Medical Center (BAMC) in Houston, Texas, marking the first Department of Defense hospital to adopt this system. This installation is part of a 5-year contract with the US Federal Government, positioning Cyclopharm as a significant player in the US market. The deployment at BAMC, the largest military medical facility in the US, is a strategic move to expand Technegas® usage across other Veteran Administration and DoD hospitals, enhancing Cyclopharm’s market presence and growth opportunities.
Cyclopharm Limited has announced a revised date for its Annual General Meeting, now scheduled for May 30, 2025, with the election of directors as a key agenda item. The new deadline for director nominations is set for April 9, 2025. This announcement, approved by CEO James McBrayer, is significant for stakeholders as it outlines the company’s governance timeline and potential leadership changes.
Cyclopharm Limited has released its corporate governance statement for the financial year ending December 31, 2024, which is available on their website. The statement outlines the company’s adherence to the ASX Corporate Governance Council’s principles, highlighting their commitment to transparency and accountability in management and oversight. This announcement reinforces Cyclopharm’s dedication to maintaining high governance standards, potentially strengthening its position in the market and assuring stakeholders of its robust governance practices.
Cyclopharm Limited has released its 2024 Annual Report, highlighting its position as a global leader in functional lung ventilation imaging. The report underscores the company’s commitment to innovation and its strong market presence with Technegas™, which is widely used in 66 countries, reflecting its significant impact on the healthcare industry.
Cyclopharm Limited announced its participation in the NWR Virtual Healthcare Conference, where CEO James McBrayer will present. This engagement highlights Cyclopharm’s ongoing efforts to engage with stakeholders and showcase its advancements in nuclear medicine, potentially enhancing its industry positioning and stakeholder relations.
Cyclopharm Limited announced a business update scheduled for March 19, 2025, which will cover the company’s FY 2024 results, a new five-year contract with the USA Veterans Administration, and progress in USA commercialization. This update signifies Cyclopharm’s strategic advancements in the U.S. market, potentially enhancing its industry positioning and stakeholder value.
Cyclopharm Limited has secured a five-year Federal Supply Schedule agreement with the US Veterans Health Administration, marking a significant expansion of its Technegas product within the US federal healthcare system. This agreement simplifies procurement processes and ensures a consistent supply of Technegas, strengthening Cyclopharm’s position in the US market despite uncertainties in healthcare funding policies.